ClinicalTrials.gg
CompletedNCT06462404Updated Jun 4, 2025

A Study to Evaluate the Efficacy, Safety, and Tolerability of E2086 Compared to Placebo and Active Comparator in Adult Participants With Narcolepsy Type 1

A Phase 1 interventional study of E2086 and E2086 Placebo in Narcolepsy Type 1 (NT1), sponsored by Eisai Inc.. Completed at 14 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-04.

Sponsored by Eisai Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Mar 2025, 1 year 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
22
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 85 studies in Narcolepsy with a site in United States — 19 open to participants now, 20 under way, 8 of them phase 3. Narcolepsy · United States.

Enrollment
59th of 69
22 · median 93
Started
2024
with 6 others
Phase 1
13 of 85
1 open now
Registered
65th of 85
by date

Among the 85 studies in Narcolepsy with a site in United States, this one is the 59th largest by enrollment of the 69 interventional ones that give a count, is one of 7 that started in 2024, is one of 13 in phase 1, and was the 65th registered.

Narcolepsy

158 studies on the registry are indexed under Narcolepsy; 38 are open to participants now.

Browse Narcolepsy studies →

Open to participants now

19 of the 85 studies in Narcolepsy with a site in United States are open now. Recruiting first, the newest first:

14 more — sign in →

All 19 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 30 Narcolepsy studies recruiting now, 12 (40%) set no upper age limit and 16 (53%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 85 studies in Narcolepsy with a site in United States, or all of them as a file.
02

Study summary

The primary purpose of this study is to evaluate the efficacy of single oral doses of E2086 compared to placebo in the treatment of excessive daytime sleepiness (EDS) as assessed by the Maintenance of Wakefulness Test (MWT) in adult participants with narcolepsy type 1 (NT1).

03

Conditions studied

  • Narcolepsy Type 1 (NT1)

Browse trials for

Keywords

  • Narcolepsy
  • E2086
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, age greater than or equal to (>=) 18 years at the time of
  2. Diagnosis of NT1 defined by the following criteria:

    • History of daily periods of the irrepressible need to sleep, or daytime lapses into sleep, occurring for at least 3 months
    • History of cataplexy (which must be confirmed during the Screening Period by Sleep/Cataplexy Diary)
    • At least one of the following:

      • On Screening multiple sleep latency test (MSLT): MSL of less than or equal to (\<=) 8 minutes and 2 or more sleep onset rapid eye movement periods (SOREMPs) on an MSLT performed according to standard techniques
      • On Screening nocturnal polysomnography (PSG): One or more SOREMPs within 15 minutes of sleep onset
  3. Epworth Sleepiness Scale score >=10
  4. Reports regular bedtime, defined as the time that the participant attempts to sleep, between 22:00 and midnight (based on data from the Screening Sleep/Cataplexy Diary)
  5. Reports regular waketime, defined at the time the participant gets out of bed for the day, between 05:00 and 10:00 (based on data from the Screening Sleep/Cataplexy Diary)
  6. Reports being in bed between 7 and 9 hours per night (based on data from the Screening Sleep/Cataplexy Diary)
  7. (BMI) >=18 to less than (\<) 40 kilograms per meter square (kg/m\^2), at Screening

Exclusion criteria

Exclusion Criteria

  1. Females who are breastfeeding or pregnant at Screening or Baseline (as documented by a positive beta-human chorionic gonadotropin [ß-hCG] or human chorionic gonadotropin [hCG] test with a minimum sensitivity of 25 international units per liter (IU/L) or equivalent units of ß-hCG [or hCG]), and females who are breastfeeding or pregnant during the Treatment Period. A separate baseline assessment is required if a negative screening pregnancy test was obtained more than 72 hours before the 1st dose of study drug
  2. Females of who:

    • Within 28 days before study entry, did not use a highly effective method of , which includes any of the following:

      • total abstinence (if it is their preferred and usual lifestyle)
      • a nonhormonal intrauterine device (example, "coil") or a progesterone-only intrauterine hormone-releasing system
      • a nonsteroidal oral contraceptive (participant must have been on a stable dose of the same nonsteroidal oral contraceptive product for at least 28 days before dosing and must agree to stay on the same dose of the oral contraceptive throughout the study and for 28 days after study drug discontinuation.)
      • depot medroxyprogesterone acetate or depot norethisterone enantate.
      • have a vasectomized partner with confirmed azoospermia.
    • Do not agree to use a highly effective method of contraception (as described above) throughout the entire study period and for 30 days after study drug administration.

      • Participants on an oral contraceptive must use an additional barrier method throughout the study and for 30 days after study drug administration.

    NOTE: All females will be considered to be of childbearing potential unless they are (amenorrheic for at least 12 consecutive months, in the appropriate age group, and without other known or suspected cause) or have been sterilized surgically (that are, bilateral tubal ligation, total hysterectomy, or bilateral oophorectomy, all with surgery at least 1 month before dosing).

  3. Males who have not had a successful vasectomy (confirmed azoospermia) if their female partners meet the exclusion criteria above that is, the female partners are of childbearing potential and are not willing to use a highly effective contraceptive method throughout the study period and for 92 days after study drug administration. No sperm donation is allowed during the study period and for 92 days after study drug administration
  4. History of myocardial infarction, ischemic heart disease, or cardiac failure at Screening
  5. History of arrhythmia or uncontrolled arrhythmia
  6. Known to have or probable positivity for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) within 14 days of any study visit.
  7. Exposure within the last 10 days to an individual with confirmed or probable coronavirus disease-2019 (COVID-19) or symptoms within the last 10 days that are on the most recent Centers for Disease Control and Prevention (CDC) list of COVID symptoms
  8. to of the study drug (E2086), or to active comparator or any of its excipients
  9. Any suicidal ideation with intent with or without a plan at Screening or within 6 months of Screening (that is, answering "Yes" to questions 4 or 5 on the Suicidal Ideation section of the CSSRS)
  10. Any lifetime suicidal behavior (per the Suicidal Behavior section of the C-SSRS)
  11. Any history of psychiatric disease (including but not limited to depression or other mood disorders, bipolar disorder, psychotic disorders, including schizophrenia, panic attacks, anxiety disorders), within 10 years of Screening
  12. Any current psychiatric symptoms as indicated by a standard screening tool ( [DSM-5] Self-Rated Level 1 Cross-Cutting Symptom Measure - Adult)
  13. Participants with one or more 1st degree (blood) relatives who have lifetime diagnosis of bipolar type I disorder or a psychotic disorder
  14. Psychotic disorder(s) or unstable recurrent affective disorder(s) evident by use of antipsychotics within 2 years before Screening
  15. Evidence of clinically significant disease (examples, allergies; cardiac, respiratory, gastrointestinal, renal disease) that in the opinion of the investigator(s) could affect the participant's safety or interfere with the study assessments.
  16. Any clinically abnormal symptom or organ impairment found by medical history, physical examinations, vital signs, finding, or laboratory test results that require medical treatment at Screening or Baseline
  17. Any history of or concomitant medical condition that in the opinion of the investigator(s) would compromise the participant's ability to safely complete the study.
  18. History of drug or alcohol dependency or abuse within 2 years before Screening
  19. Use of illegal recreational drugs at Screening and throughout the study
  20. Intake of herbal preparations containing St. John's Wort within 4 weeks before dosing
  21. Currently enrolled in another clinical study or used any drug or device within 28 days or 5* the half-life, (whichever is longer) preceding .
  22. Evidence of disease that may influence the outcome of the study within 4 weeks before dosing (examples, psychiatric disorders and disorders of the gastrointestinal tract, liver, kidney, respiratory system, endocrine system, hematological system, neurological system, or cardiovascular system)
  23. History of formally diagnosed moderate to severe obstructive sleep apnea, current use of continuous positive airway pressure, or symptomatic restless legs syndrome
  24. Apnea-hypopnea index >=15 on Screening PSG
  25. Periodic limb movement arousal index (PLMAI)>=15 on Screening PSG
  26. Use of anti-cataplectic medications within 5* the half-life before Screening
  27. Use of psychostimulant medications, prescription and over-the-counter (OTC), within 5*the half-life before Screening

    • Examples of prohibited medications include OTC stimulants (example, pseudoephedrine), methylphenidate, amphetamines, modafinil, armodafinil, sodium oxybate, and pemoline
  28. Use of sleep promoting medications, prescription and OTC, within 28 days or 5*the half-life before Screening - Examples of prohibited medication include OTC sleep aids, trazodone, hypnotics, benzodiazepines, barbiturates, cannabinoids, and opioids.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    Sequence 1, ABECD: Placebo + E2086 Dose 1 + Active Comparator + E2086 Dose 2 + E2086 Dose 3

    Participants will receive 3 doses of E2086, an active comparator, E2086 matching placebo and active comparator matching placebo, all as oral tablets.

    Drug: E2086 · Drug: E2086 Placebo · Drug: Active Comparator · Drug: Active Comparator Placebo

  • Experimental
    Sequence 2, BCADE: E2086 Dose 1 + E2086 Dose 2 + Placebo + E2086 Dose 3 + Active Comparator

    Participants will receive 3 doses of E2086, an active comparator, E2086 matching placebo and active comparator matching placebo, all as oral tablets.

    Drug: E2086 · Drug: E2086 Placebo · Drug: Active Comparator · Drug: Active Comparator Placebo

  • Experimental
    Sequence 3, CDBEA: E2086 Dose 2 + E2086 Dose 3 + E2086 Dose 1 + Active Comparator + Placebo

    Participants will receive 3 doses of E2086, an active comparator, E2086 matching placebo and active comparator matching placebo, all as oral tablets.

    Drug: E2086 · Drug: E2086 Placebo · Drug: Active Comparator · Drug: Active Comparator Placebo

  • Experimental
    Sequence 4, DECAB: E2086 Dose 3 + Active Comparator + E2086 Dose 2 + Placebo + E2086 Dose 1

    Participants will receive 3 doses of E2086, an active comparator, E2086 matching placebo and active comparator matching placebo, all as oral tablets.

    Drug: E2086 · Drug: E2086 Placebo · Drug: Active Comparator · Drug: Active Comparator Placebo

  • Experimental
    Sequence 5, EADBC: Active Comparator + Placebo + E2086 Dose 3 + E2086 Dose 1 + E2086 Dose 2

    Participants will receive 3 doses of E2086, an active comparator, E2086 matching placebo and active comparator matching placebo, all as oral tablets.

    Drug: E2086 · Drug: E2086 Placebo · Drug: Active Comparator · Drug: Active Comparator Placebo

  • Experimental
    Sequence 6, DCEBA: E2086 Dose 3 + E2086 Dose 2 + Active Comparator + E2086 Dose 1 + Placebo

    Participants will receive 3 doses of E2086, an active comparator, E2086 matching placebo and active comparator matching placebo, all as oral tablets.

    Drug: E2086 · Drug: E2086 Placebo · Drug: Active Comparator · Drug: Active Comparator Placebo

  • Experimental
    Sequence 7, EDACB: Active Comparator + E2086 Dose 3 + Placebo + E2086 Dose 2 + E2086 Dose 1

    Participants will receive 3 doses of E2086, an active comparator, E2086 matching placebo and active comparator matching placebo, all as oral tablets.

    Drug: E2086 · Drug: E2086 Placebo · Drug: Active Comparator · Drug: Active Comparator Placebo

  • Experimental
    Sequence 8, AEBDC: Placebo + Active Comparator + E2086 Dose 1 + E2086 Dose 3 + E2086 Dose 2

    Participants will receive 3 doses of E2086, an active comparator, E2086 matching placebo and active comparator matching placebo, all as oral tablets.

    Drug: E2086 · Drug: E2086 Placebo · Drug: Active Comparator · Drug: Active Comparator Placebo

  • Experimental
    Sequence 9, BACED: E2086 Dose 1 + Placebo + E2086 Dose 2 + Active Comparator + E2086 Dose 3

    Participants will receive 3 doses of E2086, an active comparator, E2086 matching placebo and active comparator matching placebo, all as oral tablets.

    Drug: E2086 · Drug: E2086 Placebo · Drug: Active Comparator · Drug: Active Comparator Placebo

  • Experimental
    Sequence 10, CBDAE: E2086 Dose 2 + E2086 Dose 1 + E2086 Dose 3 + Placebo + Active Comparator

    Participants will receive 3 doses of E2086, an active comparator, E2086 matching placebo and active comparator matching placebo, all as oral tablets.

    Drug: E2086 · Drug: E2086 Placebo · Drug: Active Comparator · Drug: Active Comparator Placebo

Interventions

  • DrugE2086

    E2086 oral tablets.

  • DrugE2086 Placebo

    E2086 matching placebo tablet.

  • DrugActive Comparator

    Active comparator oral tablets.

  • DrugActive Comparator Placebo

    Active comparator matching placebo tablet.

06

What researchers measure

Primary outcomes

  1. Mean Sleep Latency (MSL) as Assessed by the 4 Maintenance of Wakefulness Tests (MWTs) for E2086 Versus Placebo at Day 1

    Sleep latency is defined as the amount of time a person takes to fall asleep. The MWT is an objective assessment of excessive daytime sleepiness (EDS) which consists of measurement tests. A participant undergoes four 40-minute wake trials, where an increased ability to stay awake in the context of trying to remain awake is reflected in a prolonged sleep latency. These measurements of sleep latency at regular intervals across the day are averaged to calculate the mean sleep latency. The MWT will be performed as per the 2021 guidance of the American Academy of Sleep Medicine.

    Time frame: At Day 1

  2. MSL as Assessed by the 4 MWTs for E2086 Versus Placebo at Day 5

    Sleep latency is defined as the amount of time a person takes to fall asleep. The MWT is an objective assessment of EDS which consists of measurement tests. A participant undergoes four 40-minute wake trials, where an increased ability to stay awake in the context of trying to remain awake is reflected in a prolonged sleep latency. These measurements of sleep latency at regular intervals across the day are averaged to calculate the mean sleep latency. The MWT will be performed as per the 2021 guidance of the American Academy of Sleep Medicine.

    Time frame: At Day 5

  3. MSL as Assessed by the 4 MWTs for E2086 Versus Placebo at Day 9

    Sleep latency is defined as the amount of time a person takes to fall asleep. The MWT is an objective assessment of EDS which consists of measurement tests. A participant undergoes four 40-minute wake trials, where an increased ability to stay awake in the context of trying to remain awake is reflected in a prolonged sleep latency. These measurements of sleep latency at regular intervals across the day are averaged to calculate the mean sleep latency. The MWT will be performed as per the 2021 guidance of the American Academy of Sleep Medicine.

    Time frame: At Day 9

  4. MSL as Assessed by the 4 MWTs for E2086 Versus Placebo at Day 13

    Sleep latency is defined as the amount of time a person takes to fall asleep. The MWT is an objective assessment of EDS which consists of measurement tests. A participant undergoes four 40-minute wake trials, where an increased ability to stay awake in the context of trying to remain awake is reflected in a prolonged sleep latency. These measurements of sleep latency at regular intervals across the day are averaged to calculate the mean sleep latency. The MWT will be performed as per the 2021 guidance of the American Academy of Sleep Medicine.

    Time frame: At Day 13

  5. MSL as Assessed by the 4 MWTs for E2086 Versus Placebo at Day 17

    Sleep latency is defined as the amount of time a person takes to fall asleep. The MWT is an objective assessment of EDS which consists of measurement tests. A participant undergoes four 40-minute wake trials, where an increased ability to stay awake in the context of trying to remain awake is reflected in a prolonged sleep latency. These measurements of sleep latency at regular intervals across the day are averaged to calculate the mean sleep latency. The MWT will be performed as per the 2021 guidance of the American Academy of Sleep Medicine.

    Time frame: At Day 17

Secondary outcomes

  1. MSL as Assessed by the 4 MWTs for E2086 Versus Active Comparator

    Sleep latency is defined as the amount of time a person takes to fall asleep. The MWT is an objective assessment of EDS which consists of measurement tests. A participant undergoes four 40-minute wake trials, where an increased ability to stay awake in the context of trying to remain awake is reflected in a prolonged sleep latency. These measurements of sleep latency at regular intervals across the day are averaged to calculate the mean sleep latency. The MWT will be performed as per the 2021 guidance of the American Academy of Sleep Medicine.

    Time frame: Days 1, 5, 9, 13 and 17

  2. Karolinska Sleepiness Scale (KSS) Score for E2086 Versus Active Comparator

    The KSS is a subjective measure of an individual's level of sleepiness during the last 10 minutes, as assessed at a particular time of day. The KSS is rated on a 10-point scale, from 1 = extremely alert, to 10 = extremely sleepy, falls asleep all the time. Higher score indicates more sleepiness.

    Time frame: Day 1 up to Day 18

  3. KSS Score for E2086 Versus Placebo

    The KSS is a subjective measure of an individual's level of sleepiness during the last 10 minutes, as assessed at a particular time of day. The KSS is rated on a 10-point scale, from 1 = extremely alert, to 10 = extremely sleepy, falls asleep all the time. Higher score indicates more sleepiness.

    Time frame: Day 1 up to Day 18

  4. Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Time frame: From first dose of study drug up to Day 20

  5. Number of Participants With Markedly Abnormal Clinical Laboratory Values

    Clinical laboratory will include hematology, chemistry, and urinalysis.

    Time frame: Baseline up to Day 20

  6. Number of Participants With Markedly Abnormal Vital Sign Values

    Vital sign parameters will include systolic and diastolic blood pressure, pulse, respiratory rate, body temperature.

    Time frame: Baseline up to Day 20

  7. Number of Participants With Markedly Abnormal Electrocardiogram (ECGs) Findings

    Time frame: Baseline up to Day 20

  8. Number of Participants With Markedly Abnormal Electroencephalogram (EEGs) Findings

    Time frame: Baseline up to Day 20

  9. Number of Participants With Suicidality as Assessed by Columbia - Suicide Severity Rating Scale (C-SSRS)

    Suicidality will be assessed using the C-SSRS. The C-SSRS assesses an individual's degree of suicidality, including suicidal ideation and suicidal behavior. The C-SSRS is an interview-based rating scale to systematically assess any suicidality, suicidal behavior, or suicidal ideation. Any suicidality is emergence of any suicidal ideation or suicidal behavior. Any suicidal behavior is indicated when response is "yes" for any these questions- actual attempt to suicide, engaged in non-suicidal self-injurious behavior, interrupted attempt, aborted attempt, preparatory acts. Any suicidal ideation is indicated when response is "yes" for any of these questions- wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with methods without intent to act or some intent to act, without specific plan or with specific plan and intent to suicide.

    Time frame: Baseline up to Day 20

  10. Cmax: Maximum Observed Plasma Concentration of E2086 and its Metabolite M1

    Time frame: Days 1, 5, 9, 13 and 17: 0-24 hours post-dose

  11. Tmax: Time to Reach Cmax of E2086 and its Metabolite M1

    Time frame: Days 1, 5, 9, 13 and 17: 0-24 hours post-dose

  12. AUC(0-t): Area Under the Plasma Concentration-time Curve From Zero Time to Time of Last Quantifiable Concentration of E2086 and its Metabolite M1

    Time frame: Days 1, 5, 9, 13 and 17: 0-24 hours post-dose

  13. AUC(0-inf): Area Under the Plasma Concentration-time Curve From Zero Time Extrapolated to Infinite of E2086 and its Metabolite M1

    Time frame: Days 1, 5, 9, 13 and 17: 0-24 hours post-dose

  14. t½: Terminal Phase Half-life of E2086 and its Metabolite M1

    Time frame: Days 1, 5, 9, 13 and 17: 0-24 hours post-dose

  15. MRp: Metabolite Ratio of AUC(0-inf)

    MRp will be calculated as ratio of plasma AUC(0-inf) of metabolite to parent following molar correction.

    Time frame: Days 1, 5, 9, 13 and 17: 0-24 hours post-dose

07

Study locations

14 sites
  • SDS Clinical Trials
    Santa Ana, California 48911, United States
  • PharmaDev Clinical Research
    Miami, Florida 33126, United States
  • Sleep Practioners, LLC
    Macon, Georgia 31210, United States
  • Clinical Research Institute
    Stockbridge, Georgia 30281, United States
  • Sound Asleep Research, Inc.
    Lansing, Michigan 48911, United States
  • Research Carolina Elite
    Denver, North Carolina 28037, United States
  • Medical Care Inc.
    Goldsboro, North Carolina 27534, United States
  • Advances Repiratory and Sleep Medicine
    Greensboro, North Carolina 27410, United States
  • Intrepid Research, LLC
    Cincinnati, Ohio 45245, United States
  • Bogan Sleep Consultants, LLC
    Columbia, South Carolina 29201, United States
  • Sleep Therapy and Research Center
    San Antonio, Texas 78229, United States
  • Comprehensive Sleep Medicine Associates
    Sugar Land, Texas 77478, United States
  • AMDX Inc.
    Markham, Ontario L3R 1A3, Canada
  • Jodha Tishon Inc
    Toronto, Ontario M5S 3A3, Canada
08

References and documents

Individual participant data

Plan to share: Yes — Eisai's data sharing commitment and further information on how to request data can be found on our website http://eisaiclinicaltrials.com/.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2024 to primary completion in Mar 2025, 8 months.

Of 13 phase 1 interventional studies under Narcolepsy, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 11. This study's 8 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 12, 2024
First posted
Jun 17, 2024
StartActual
Jun 20, 2024
Primary completionActual
Mar 17, 2025
CompletionActual
Mar 17, 2025
Last update
Jun 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06462404
Lead sponsor
Eisai Inc.
Responsible party
Sponsor
First posted
Jun 17, 2024
Start date
Jun 20, 2024
Primary completion
Mar 17, 2025
Completion
Mar 17, 2025
Last update
Jun 4, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ledasorexton

Start the discussion